• 1
    Henriksson F, Agardh C, Berne C. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248:38796.
  • 2
    WHO. WHO diabetes database 2000. Available from:[Accessed January 15, 2004].
  • 3
    Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998;2446:4618.
  • 4
    Henriksson F, Agardh CD, Berne C, Bolinder J, Jonsson B. Health economics analysis of diabetes is necessary. It facilitates decision-making and international comparison. Lakartidningen 1999;96:391516.
  • 5
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:83753.
  • 6
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:97786.
  • 7
    Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999;15:426.
  • 8
    Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001;161:16539.
  • 9
    Frier BM. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes? Int J Clin Pract 2002;129(Suppl.):S1219.
  • 10
    United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24. A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128:16575.
  • 11
    Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:93748.
  • 12
    McCrimmon RJ, Frier BM. Hypoglycaemia, the most feared complication of insulin therapy. Diabetes Metab 1994;20:50312.
  • 13
    Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:117680.
  • 14
    Allicar MP, Megas F, Houzard S, et al. Augendre-Ferrante B. Frequency and costs of hospital stays for hypoglycemia in France in 1995. Presse Med 2000; 29:65761.
  • 15
    Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002;25:210910.
  • 16
    Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60:42962.
  • 17
    Rice DP. Estimating the cost of illness. Am J Public Health Nations Health 1967;57:42440.
  • 18
    Gold MF. Frequency of severe hypoglycaemia in patients with Type I diabetes with impaired awareness of hypoglycaemia. Diabetes Care 1994;17:697703.
  • 19
    O’Brien JA, Shomphe LA, Kavanagh PL, et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:11228.
  • 20
    LINFO. FASS Läkemedel i Sverige. Oslo: Läkemedelsinformation AB, 2001.
  • 21
    Nordfeldt S, Jonsson D. Short-term effects of severe hypoglycaemia in children and adolescents with type 1 diabetes. A cost-of-illness study. Acta Paediatr 2001;90:13742.
  • 22
    Statistic Sweden. National statistics. Stockholm: Statistic Sweden, 2003. Available at [Accessed December 15, 2003].
  • 23
    Resource utilization and costs of care in the diabetes control and complications trial. Diabetes Care 1995;18:146878.
  • 24
    The Swedish Diabetes Association (Svenska Diabetes Förbundet), 2003. Available at [Accessed December 20, 2003].
  • 25
    Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:73541.